Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

In a phase 2 trial involving participants taking a nucleoside or nucleotide analogue, 23% of those assigned to receive xalnesiran plus pegylated interferon alfa-2a had HBsAg loss at 24 weeks after the end of treatment.

​   The New England Journal of Medicine: Search Results in Infectious Disease